<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132466</url>
  </required_header>
  <id_info>
    <org_study_id>3333934_C</org_study_id>
    <nct_id>NCT04132466</nct_id>
  </id_info>
  <brief_title>ASSURE WCD Clinical Evaluation - Conversion Efficacy Study</brief_title>
  <acronym>ACE-CONVERT</acronym>
  <official_title>ASSURE WCD Clinical Evaluation - Conversion Efficacy Study (ACE-CONVERT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kestra Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regulatory and Clinical Research Institute Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kestra Medical Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter single arm open label evaluation of the ASSURE Wearable Cardioverter&#xD;
      Defibrillator (WCD) defibrillation waveform in adult cardiac patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate Ventricular Tachycardia/Ventricular Fibrillation&#xD;
      (VT/VF) conversion efficacy in adult human subjects using the ASSURE Wearable Cardioverter&#xD;
      Defibrillator (WCD) defibrillation waveform.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Actual">March 19, 2020</completion_date>
  <primary_completion_date type="Actual">March 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter single arm open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative first and second shock VT/VF conversion rate</measure>
    <time_frame>Through study procedure completion, average of 2 hours</time_frame>
    <description>The ratio of the number of subjects with successful (first or second shock) arrhythmia conversion using the Test System to the number of total inductions attempted with shocks delivered by the Test System. A successful arrhythmia conversion is defined as termination of an induced ventricular rhythm by first or second shock from the Test System to a non-shockable rhythm (rhythms other than VT or VF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First shock VT/VF conversion rate</measure>
    <time_frame>Through study procedure completion, average of 2 hours</time_frame>
    <description>The ratio of the number of subjects with successful (first shock) arrhythmia conversion using the Test System to the number of total inductions attempted with shocks delivered by the Test System. A successful arrhythmia conversion is defined as termination of an induced ventricular rhythm by first shock from the Test System to a non-shockable rhythm (rhythms other than VT or VF).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through study procedure completion, average of 2 hours</time_frame>
    <description>Summary of adverse events that in the judgement of the investigator are at least possibly related to use of the investigational Test System.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Death, Sudden, Cardiac</condition>
  <arm_group>
    <arm_group_label>Enrolled Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult subjects who met eligibility criteria and provided written informed consent to participate</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system</intervention_name>
    <description>defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator</description>
    <arm_group_label>Enrolled Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, age â‰¥ 18 years&#xD;
&#xD;
          2. Able and willing to provide written informed consent before undergoing any&#xD;
             study-related procedures&#xD;
&#xD;
          3. Scheduled for any of the following procedures:&#xD;
&#xD;
               1. Electrophysiology study for induction of ventricular arrhythmias&#xD;
&#xD;
               2. Non-invasive electrophysiology testing using an existing implantable&#xD;
                  defibrillator&#xD;
&#xD;
               3. Implantable cardioverter-defibrillator (ICD) replacement procedure during which&#xD;
                  induction of a ventricular arrhythmia is planned&#xD;
&#xD;
               4. Ablation of ventricular tachycardia (patients undergoing ventricular tachycardia&#xD;
                  ablation in which only a substrate modification approach is planned, with no&#xD;
                  intention of inducing a ventricular arrhythmia, should not be included)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition that by the judgement of the physician investigator precludes the&#xD;
             subject's ability to comply with the study requirements&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Use of mechanical circulatory support (e.g. Left Ventricular Assist Device, Total&#xD;
             Artificial Heart, intraaortic balloon pump or Impella)&#xD;
&#xD;
          4. Documented nonchronic cardiac thrombus&#xD;
&#xD;
          5. Atrial fibrillation or atrial flutter without therapeutic systemic anticoagulation&#xD;
&#xD;
          6. Critical aortic stenosis&#xD;
&#xD;
          7. Unstable coronary artery disease (CAD)&#xD;
&#xD;
          8. Recent stroke or transient ischemic attack (TIA)&#xD;
&#xD;
          9. Hemodynamic instability&#xD;
&#xD;
         10. Currently implanted Boston Scientific S-ICD (due to location of implant relative to&#xD;
             test system)&#xD;
&#xD;
         11. Unstable angina&#xD;
&#xD;
         12. New York Heart Association (NYHA) Class IV&#xD;
&#xD;
         13. Left Ventricular Ejection Fraction (LVEF) &lt; 20%&#xD;
&#xD;
         14. Any medical condition that by the judgement of the physician investigator, patient&#xD;
             participation in this study is not in the best interest of the patient&#xD;
&#xD;
         15. History of difficulty of ventricular arrhythmia induction&#xD;
&#xD;
         16. Amiodarone use within 3 months before the study procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marye Gleva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alaska Cardiovascular Research Foundation, Inc.</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Research and Innovation MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <disposition_first_submitted>September 1, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>September 1, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 3, 2020</disposition_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

